|Bid||118.16 x 800|
|Ask||118.23 x 1000|
|Day's range||115.03 - 120.49|
|52-week range||115.03 - 376.65|
|Beta (5Y monthly)||1.69|
|PE ratio (TTM)||3.66|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||217.86|
A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.
The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.